• Vivos Therapeutics (VVOS) stock is rising alongside positive news from the U.S. Food and Drug Administration (FDA).
  • The FDA has granted approval to the company’s sleep apnea treatment device.
  • With that comes heavy trading of VVOS stock on Wednesday.

Vivos Therapeutics (NASDAQ:VVOS) stock is rocketing higher on Wednesday after the U.S. Food and Drug Administration (FDA) granted approval to its sleep apnea treatment device.

According to a press release from the company, it has been granted 510(k) clearance from the FDA for its removable CARE oral applications. That covers its DNA oral appliance, mRNA oral appliance and its mmRNA oral appliance.

Vivos points out that this is the first approval from the FDA for a device to treat patients with severe obstructive sleep apnea without CPAP or surgical neurostimulation implants. The treatment is approved for adults age 18 and over.

Kirk Huntsman, Chairman and CEO of Vivos Therapeutics, said the following about the news:

“This approval could also clear the way for greater reimbursement levels from medical insurance payors and Medicare. We believe that all these factors should favorably impact our ability to grow our revenues in 2024 and beyond.”

‍

Track all markets on TradingView

‍

Disclaimers: This content is made for entertainment purposes only. This is not financial advice.